ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

This study has been completed.

Sponsored by: Alnylam Pharmaceuticals
Information provided by: Alnylam Pharmaceuticals
ClinicalTrials.gov Identifier: NCT00496821
  Purpose

The purpose of this study is to determine the safety, tolerability and efficacy of intranasal ALN-RSV01 versus placebo, administered once daily for 5 days to a healthy male volunteers experimentally inoculated with RSV


Condition Intervention Phase
Respiratory Syncytial Virus Infections
Drug: ALN-RSV01
Phase II

MedlinePlus related topics:   Respiratory Syncytial Virus Infections   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:   A Study to Investigate the Safety and Efficacy of Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus

Further study details as provided by Alnylam Pharmaceuticals:

Primary Outcome Measures:
  • Safety and tolerability of intranasal ALN-RSV01 versus placebo, administered in a multiple-dose schedule (once daily for 5 days) to healthy adult volunteers experimentally inoculated with respiratory syncytial virus [ Time Frame: 28 days ]

Secondary Outcome Measures:
  • Determining the impact of ALN-RSV01 on symptoms of RSV infection, RSV infection rate based upon measures of viral load, and understanding the potential antiviral activity of ALN-RSV01 [ Time Frame: 28 days ]

Estimated Enrollment:   88
Study Start Date:   July 2007
Study Completion Date:   November 2007

  Eligibility
Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Criteria

Inclusion Criteria:

  • Availability for the required study period (including the inpatient phase, ability to comply with study requirements and attend follow-up study visits
  • Able to provide written consent for participation after reading the Consent Form and after having adequate opportunity to discuss the study with an investigator or qualified deputy.
  • Good general health status as determined by a screening evaluation no greater than 120 days but not less than 14 days prior to enrollment and admission to the research unit
  • Low titers of RSV neutralizing antibody measured during screening.

Exclusion Criteria:

  • Significant acute or chronic, uncontrolled medical illness
  • Presence of household member or close contact to someone who:

    • Is less than three(3) years of age
    • Has a known immunodeficiency
    • Is receiving immunosuppressant drugs
    • Is undergoing or soon to undergo cancer chemotherapy within 28 days of enrollment
    • Has diagnosed emphysema, chronic obstructive pulmonary disease(COPD), or severe lung disease
    • Is elderly and residing in a nursing home, or
    • Has received an organ transplant
  • Females are not eligible for this study
  • Evidence of or history of drug or alcohol abuse (within the past 6 months) or positive urine drug or alcohol screen

Other protocol-defined inclusion/exclusion criteria may apply.

  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00496821

Locations
United States, Massachusetts
Alnylam Pharmaceuticals    
      Cambridge, Massachusetts, United States, 02142

Sponsors and Collaborators
Alnylam Pharmaceuticals

Investigators
Study Director:     Akshay Vaishnaw, MD PhD     Alnylam Pharmaceuticals    
  More Information


Study ID Numbers:   ALN-RSV01-105
First Received:   July 3, 2007
Last Updated:   November 29, 2007
ClinicalTrials.gov Identifier:   NCT00496821
Health Authority:   United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by Alnylam Pharmaceuticals:
Respiratory Syncytial Virus  

Study placed in the following topic categories:
Virus Diseases
Paramyxoviridae Infections
Respiratory Syncytial Virus Infections

Additional relevant MeSH terms:
RNA Virus Infections
Pneumovirus Infections
Infection
Mononegavirales Infections

ClinicalTrials.gov processed this record on November 30, 2008




Links to all studies - primarily for crawlers